A phase II study of bisantrene in malignant lymphomas: a southwest oncology group study
Forty evaluable patients with malignant lymphoma (ML) were treated with bisantrene at a dose of 260 mg/m2 every 3 weeks (18 patients) or 208 mg/m2 every 3 weeks (22 patients). The initial dose rate was determined on the basis of expected myelosuppression. Patients were heavily pretreated and had adv...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1986, Vol.16 (1), p.67-69 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 69 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 16 |
| creator | MILLER, T. P COWAN, J. D NEILAN, B. A JONES, S. E |
| description | Forty evaluable patients with malignant lymphoma (ML) were treated with bisantrene at a dose of 260 mg/m2 every 3 weeks (18 patients) or 208 mg/m2 every 3 weeks (22 patients). The initial dose rate was determined on the basis of expected myelosuppression. Patients were heavily pretreated and had advanced disease (92% had stage IV). The overall response rate was 10% and included 1 partial response (PR) in 17 patients with Hodgkin's disease (HD), 1 PR and 1 complete response (CR) in 5 patients with favorable histology in non-Hodgkin's lymphoma (NHL), and 1 PR in 18 patients with unfavorable histology in NHL. Neutropenia (WBC less than or equal to 3000 cells/microliter) was the most common toxicity, occurring in 50% of patients. Phlebitis was a common side effect in patients treated with bisantrene administered by way of peripheral veins. Bisantrene has limited activity in heavily pretreated patients with HD or unfavorable histology in NHL. The role of bisantrene for treatment of NHL with favorable histology or for treatment at an earlier point in the natural history of ML is unknown. |
| doi_str_mv | 10.1007/BF00255289 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00255289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3940222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-ea4edaf46219999e5d708e4748fefa6e22b36b6fe48d31ed55e4bfeba21911ea3</originalsourceid><addsrcrecordid>eNpFkEtLw0AUhQdRaq1u3AuzcCVE7zzyqLu2WC0U3Cguw01yp40kmTCTIPn3Rlrq3Ry45-MsPsZuBTwKgPhpuQaQYSiT-RmbCq1kAIlW52wKSusgjEFfsivvvwFAC6UmbKLmGqSUU_a14O0ePfHNhvuuLwZuDc9Kj03nqCFeNrzGqtw144NXQ93ubY3-mSP3tu_2P-Q7bpvcVnY38J2zfXuYuWYXBitPN8ecsc_1y8fqLdi-v25Wi22QKyG6gFBTgUZHUszHo7CIISEd68SQwYikzFSURYZ0UihBRRiSzgxlOPJCEKoZezjs5s5678ikrStrdEMqIP2Tk_7LGeG7A9z2WU3FCT3aGPv7Y48-x8o4bPLSn7AkEsloVP0C_kVsfA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase II study of bisantrene in malignant lymphomas: a southwest oncology group study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>MILLER, T. P ; COWAN, J. D ; NEILAN, B. A ; JONES, S. E</creator><creatorcontrib>MILLER, T. P ; COWAN, J. D ; NEILAN, B. A ; JONES, S. E</creatorcontrib><description>Forty evaluable patients with malignant lymphoma (ML) were treated with bisantrene at a dose of 260 mg/m2 every 3 weeks (18 patients) or 208 mg/m2 every 3 weeks (22 patients). The initial dose rate was determined on the basis of expected myelosuppression. Patients were heavily pretreated and had advanced disease (92% had stage IV). The overall response rate was 10% and included 1 partial response (PR) in 17 patients with Hodgkin's disease (HD), 1 PR and 1 complete response (CR) in 5 patients with favorable histology in non-Hodgkin's lymphoma (NHL), and 1 PR in 18 patients with unfavorable histology in NHL. Neutropenia (WBC less than or equal to 3000 cells/microliter) was the most common toxicity, occurring in 50% of patients. Phlebitis was a common side effect in patients treated with bisantrene administered by way of peripheral veins. Bisantrene has limited activity in heavily pretreated patients with HD or unfavorable histology in NHL. The role of bisantrene for treatment of NHL with favorable histology or for treatment at an earlier point in the natural history of ML is unknown.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00255289</identifier><identifier>PMID: 3940222</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Anthracenes - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Drug Evaluation ; Hodgkin Disease - drug therapy ; Hodgkin Disease - pathology ; Humans ; Lymphoma - drug therapy ; Lymphoma - pathology ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Cancer chemotherapy and pharmacology, 1986, Vol.16 (1), p.67-69</ispartof><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-ea4edaf46219999e5d708e4748fefa6e22b36b6fe48d31ed55e4bfeba21911ea3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8618034$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3940222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MILLER, T. P</creatorcontrib><creatorcontrib>COWAN, J. D</creatorcontrib><creatorcontrib>NEILAN, B. A</creatorcontrib><creatorcontrib>JONES, S. E</creatorcontrib><title>A phase II study of bisantrene in malignant lymphomas: a southwest oncology group study</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Forty evaluable patients with malignant lymphoma (ML) were treated with bisantrene at a dose of 260 mg/m2 every 3 weeks (18 patients) or 208 mg/m2 every 3 weeks (22 patients). The initial dose rate was determined on the basis of expected myelosuppression. Patients were heavily pretreated and had advanced disease (92% had stage IV). The overall response rate was 10% and included 1 partial response (PR) in 17 patients with Hodgkin's disease (HD), 1 PR and 1 complete response (CR) in 5 patients with favorable histology in non-Hodgkin's lymphoma (NHL), and 1 PR in 18 patients with unfavorable histology in NHL. Neutropenia (WBC less than or equal to 3000 cells/microliter) was the most common toxicity, occurring in 50% of patients. Phlebitis was a common side effect in patients treated with bisantrene administered by way of peripheral veins. Bisantrene has limited activity in heavily pretreated patients with HD or unfavorable histology in NHL. The role of bisantrene for treatment of NHL with favorable histology or for treatment at an earlier point in the natural history of ML is unknown.</description><subject>Anthracenes - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - pathology</subject><subject>Humans</subject><subject>Lymphoma - drug therapy</subject><subject>Lymphoma - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLw0AUhQdRaq1u3AuzcCVE7zzyqLu2WC0U3Cguw01yp40kmTCTIPn3Rlrq3Ry45-MsPsZuBTwKgPhpuQaQYSiT-RmbCq1kAIlW52wKSusgjEFfsivvvwFAC6UmbKLmGqSUU_a14O0ePfHNhvuuLwZuDc9Kj03nqCFeNrzGqtw144NXQ93ubY3-mSP3tu_2P-Q7bpvcVnY38J2zfXuYuWYXBitPN8ecsc_1y8fqLdi-v25Wi22QKyG6gFBTgUZHUszHo7CIISEd68SQwYikzFSURYZ0UihBRRiSzgxlOPJCEKoZezjs5s5678ikrStrdEMqIP2Tk_7LGeG7A9z2WU3FCT3aGPv7Y48-x8o4bPLSn7AkEsloVP0C_kVsfA</recordid><startdate>1986</startdate><enddate>1986</enddate><creator>MILLER, T. P</creator><creator>COWAN, J. D</creator><creator>NEILAN, B. A</creator><creator>JONES, S. E</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1986</creationdate><title>A phase II study of bisantrene in malignant lymphomas: a southwest oncology group study</title><author>MILLER, T. P ; COWAN, J. D ; NEILAN, B. A ; JONES, S. E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-ea4edaf46219999e5d708e4748fefa6e22b36b6fe48d31ed55e4bfeba21911ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Anthracenes - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - pathology</topic><topic>Humans</topic><topic>Lymphoma - drug therapy</topic><topic>Lymphoma - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MILLER, T. P</creatorcontrib><creatorcontrib>COWAN, J. D</creatorcontrib><creatorcontrib>NEILAN, B. A</creatorcontrib><creatorcontrib>JONES, S. E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MILLER, T. P</au><au>COWAN, J. D</au><au>NEILAN, B. A</au><au>JONES, S. E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of bisantrene in malignant lymphomas: a southwest oncology group study</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1986</date><risdate>1986</risdate><volume>16</volume><issue>1</issue><spage>67</spage><epage>69</epage><pages>67-69</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Forty evaluable patients with malignant lymphoma (ML) were treated with bisantrene at a dose of 260 mg/m2 every 3 weeks (18 patients) or 208 mg/m2 every 3 weeks (22 patients). The initial dose rate was determined on the basis of expected myelosuppression. Patients were heavily pretreated and had advanced disease (92% had stage IV). The overall response rate was 10% and included 1 partial response (PR) in 17 patients with Hodgkin's disease (HD), 1 PR and 1 complete response (CR) in 5 patients with favorable histology in non-Hodgkin's lymphoma (NHL), and 1 PR in 18 patients with unfavorable histology in NHL. Neutropenia (WBC less than or equal to 3000 cells/microliter) was the most common toxicity, occurring in 50% of patients. Phlebitis was a common side effect in patients treated with bisantrene administered by way of peripheral veins. Bisantrene has limited activity in heavily pretreated patients with HD or unfavorable histology in NHL. The role of bisantrene for treatment of NHL with favorable histology or for treatment at an earlier point in the natural history of ML is unknown.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>3940222</pmid><doi>10.1007/BF00255289</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1986, Vol.16 (1), p.67-69 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00255289 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Anthracenes - therapeutic use Antineoplastic agents Biological and medical sciences Chemotherapy Drug Evaluation Hodgkin Disease - drug therapy Hodgkin Disease - pathology Humans Lymphoma - drug therapy Lymphoma - pathology Medical sciences Pharmacology. Drug treatments |
| title | A phase II study of bisantrene in malignant lymphomas: a southwest oncology group study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A39%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20bisantrene%20in%20malignant%20lymphomas:%20a%20southwest%20oncology%20group%20study&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=MILLER,%20T.%20P&rft.date=1986&rft.volume=16&rft.issue=1&rft.spage=67&rft.epage=69&rft.pages=67-69&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00255289&rft_dat=%3Cpubmed_cross%3E3940222%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3940222&rfr_iscdi=true |